Deepika Pakianathan, Director at Karyopharm Therapeutics Inc. (KPTI), bought 2,085,818 shares at $16.00 ($5.0M) on 2013-11-12, disclosed to the SEC on 2013-11-14.
Open-market purchase of $5.0M KPTI by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,773,318 | $0 | 0.0% |
| 2 | $16.00 | 3,022 | $48K | 1.0% |
| 3 | $16.00 | 309,478 | $5.0M | 99.0% |
| Total | $2.40 avg | 2,085,818 | $5.0M | 100% |
| Filing → |
| KPTI | SELL | 2024-06-04 | $1.4M | — | Filing → |
| CALA | SELL | 2023-01-31 | $47K | — | Filing → |
| KPTI | SELL | 2022-06-10 | $6.8M | — | Filing → |